94 related articles for article (PubMed ID: 28278706)
1. High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma.
Bernardini G; Vulpis E; Bonanni V; Stabile H; Ricciardi MR; Petrucci MT; Gismondi A; Santoni A; Zingoni A
Leuk Lymphoma; 2017 Oct; 58(10):2493-2496. PubMed ID: 28278706
[No Abstract] [Full Text] [Related]
2. IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity.
Frassanito MA; Silvestris F; Cafforio P; Silvestris N; Dammacco F
Int J Clin Lab Res; 1997; 27(1):48-54. PubMed ID: 9144027
[TBL] [Abstract][Full Text] [Related]
3. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.
Ponzetta A; Benigni G; Antonangeli F; Sciumè G; Sanseviero E; Zingoni A; Ricciardi MR; Petrucci MT; Santoni A; Bernardini G
Cancer Res; 2015 Nov; 75(22):4766-77. PubMed ID: 26438594
[TBL] [Abstract][Full Text] [Related]
4. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.
Dhodapkar MV; Geller MD; Chang DH; Shimizu K; Fujii S; Dhodapkar KM; Krasovsky J
J Exp Med; 2003 Jun; 197(12):1667-76. PubMed ID: 12796469
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
6. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.
Ray A; Das DS; Song Y; Richardson P; Munshi NC; Chauhan D; Anderson KC
Leukemia; 2015 Jun; 29(6):1441-4. PubMed ID: 25634684
[No Abstract] [Full Text] [Related]
7. Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection.
Riva A; Laird M; Casrouge A; Ambrozaitis A; Williams R; Naoumov NV; Albert ML; Chokshi S
Hepatology; 2014 Aug; 60(2):487-96. PubMed ID: 24668726
[TBL] [Abstract][Full Text] [Related]
8. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
9. Is complement C1q a potential marker for tumor burden and immunodeficiency in multiple myeloma?
Yang R; Huang J; Ma H; Li S; Gao X; Liu Y; Shen J; Liao A
Leuk Lymphoma; 2019 Jul; 60(7):1812-1818. PubMed ID: 30628497
[TBL] [Abstract][Full Text] [Related]
10. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma.
Fauriat C; Mallet F; Olive D; Costello RT
Leukemia; 2006 Apr; 20(4):732-3. PubMed ID: 16437151
[No Abstract] [Full Text] [Related]
11. Hyperreactive cellular immunity in multiple myeloma.
Reibnegger G; Wachter H; Krainer M; Ludwig H; Herold M; Huber H
Blood; 1992 Apr; 79(8):2174-6. PubMed ID: 1562745
[No Abstract] [Full Text] [Related]
12. [Studies on the mechanism of defective natural killer cytotoxicity in patients with multiple myeloma].
Funato T; Koide A; Ohtani H; Saito M
Gan No Rinsho; 1984 Apr; 30(4):368-72. PubMed ID: 6727037
[TBL] [Abstract][Full Text] [Related]
13. Modulating effects of monocytes and autologous serum on natural killer capacity in multiple myeloma patients.
Ventura MT; Crollo R; Lasaracina E
Blut; 1986 Feb; 52(2):127-8. PubMed ID: 3633201
[No Abstract] [Full Text] [Related]
14. Polyvalent immunoglobulins, platelet lysate and lenalidomide: cocktail for polyfunctional NK cells expansion for multiple myeloma.
Trébéden-Negre H; Vieillard V; Rosenzwajg M; Garderet L; Cherai M; Nguyen-Quoc S; Tanguy ML; Norol F
Bone Marrow Transplant; 2017 Mar; 52(3):480-483. PubMed ID: 27941770
[No Abstract] [Full Text] [Related]
15. A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG.
Flores RJ; Kelly AJ; Li Y; Nakka M; Barkauskas DA; Krailo M; Wang LL; Perlaky L; Lau CC; Hicks MJ; Man TK
Cancer; 2017 Jan; 123(1):144-154. PubMed ID: 27529817
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
[TBL] [Abstract][Full Text] [Related]
17. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
18. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Jungkunz-Stier I; Zekl M; Stühmer T; Einsele H; Seggewiss-Bernhardt R
Leuk Lymphoma; 2014 Jan; 55(1):168-76. PubMed ID: 23573828
[TBL] [Abstract][Full Text] [Related]
19. Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity.
Ray A; Du T; Song Y; Buhrlage SJ; Chauhan D; Anderson KC
Leukemia; 2021 Aug; 35(8):2435-2438. PubMed ID: 33487632
[No Abstract] [Full Text] [Related]
20. Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma.
Nguyen-Pham TN; Im CM; Nguyen TA; Lim MS; Hong CY; Kim MH; Lee HJ; Lee YK; Cho D; Ahn JS; Yang DH; Kim YK; Chung IJ; Kim HJ; Lee JJ
Leuk Res; 2011 Sep; 35(9):1241-7. PubMed ID: 21612823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
